RAIFFEISEN SWITZERLAND COOPERATIVE | Real-time Bid/Ask 09:41:03 2024-06-26 EDT | ||
| 104.28 CHF / 105.12 CHF | +0.17% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 104.5 | +0.51% |
Delayed Quote Swiss Exchange
Last update June 25, 2024 at 11:20 am
More quotesStatic data
| Product type | Aktienanleihen |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Raiffeisen Switzerland B.V. |
| ODNRCH | |
| ISIN | CH1282081921 |
| Date issued | 2024-04-26 |
| Strike | 733.5 $ |
| Maturity | 2025-10-27 (488 Days) |
| Parity | 1 : 1 |
| Emission price | 100 CHF |
| Emission volume | N/A |
| Settlement | Beides |
| Currency | CHF |
Technical Indicators
| Highest since issue | 104.5 CHF |
|---|---|
| Lowest since issue | 100 CHF |
| Spread | 8.4 CHF |
| Spread % | 0.80% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
904.6
USD
Average target price
860.5
USD
Spread / Average Target
-4.87%
- Stock Market
- Certificates
- ODNRCH Certificat
